Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > News out on Goblet trial with Merck

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Nov 04, 2021 10:37am

197 Views

Post# 34086492

RE:RE:RE:RE:News out on Goblet trial with Merck

Great posts guys, and I imagine many of us here have had thoughts bouncing around our heads involving Coffey & Co. holding out for 15b-20b. You're all much more knowledgeable than I concerning biotech buyouts & what ONC may be worth, but I'd take under $10b...just under;)

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management